Work

Thu0162 Likelihood of Clinical Worsening Among Rheumatoid Arthritis Patients Who Achieved a Partial Response to Adalimumab and Were Subsequently Switched to Sarilumab

Year: 2020

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2020-eular.1729

Authors: J. Curtis, D. Aletaha, G.R. Burmester, K. Ford, H. Van Hoogstraten, H. Leher, K. Thangavelu, V. Bykerk

Institutions: University of Alabama at Birmingham, Medical University of Vienna, Charité – Universitätsmedizin Berlin, Sanofi (United States), Regeneron (United States), Hospital for Special Surgery

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Gilead Sciences, Celgene, AbbVie, Regeneron Pharmaceuticals, Medac, Sanofi Genzyme, UCB Pharma

OpenAlex ID: W3092667008

Cites: 1

Cited by:

Related to: 10